

5/3,AB/61 (Item 2 from file: 764)
ALOG(R) File 764:BCC Market Research
) 2003 Business Communication Co. All rts. reserv.

157778

COMMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW: %ANTIBODIES%: PREVENTING
%PSEUDOMONAS%-INDUCED PNEUMONIA

in Title: COMMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW
ub. Date: APRIL 2001
Source: BUSINESS COMMUNICATIONS COMPANY, INCORPORATED
elephone: (203) 853-4266
rd Count: 287 (1 pp.)
Language: English

Country: UNITED STATES
Industry: BIOTECHNOLOGY, HEALTH CARE
Company Names (DIALOG Generated): Conference on Antimicrobial Agents and
Chemotherapy ; InterMune Pharmaceuticals Inc ; Medical College
of Wisconsin ; University of California San

SELECT statement is:
s pcrV

| Items | File |
|--------------------|--|
| 88 | 2: INSPEC_1969-2003/Jun W2 |
| 20 | 5: Biosis Previews(R)_1969-2003/Jun W2 |
| 174 | 6: NTIS_1964-2003/Jun W3 |
| 105 | 8: Ei Compendex(R)_1970-2003/Jun W2 |
| 4 | 9: Business & Industry(R)_Jul/1994-2003/Jun 17 |
| 1 | 15: ABI/Inform(R)_1971-2003/Jun 18 |
| 127 | 16: Gale Group PROMT(R)_1990-2003/Jun 18 |
| 3 | 18: Gale Group F&S Index(R)_1988-2003/Jun 18 |
| 2 | 19: Chem.Industry Notes_1974-2003/ISS 200324 |
| 78 | 20: Dialog Global Reporter_1997-2003/Jun 18 |
| 19 | 34: SciSearch(R) Cited Ref Sci_1990-2003/Jun W2 |
| 3 | 35: Dissertation Abs Online_1861-2003/May |
| 2 | 42: Pharmaceuticl News Idx_1974-2003/Jun W2 |
| 2 | 47: Gale Group Magazine DB(TM)_1959-2003/Jun 13 |
| 1 | 50: CAB Abstracts_1972-2003/May |
| 3 | 63: Transport Res(TRIS)_1970-2003/May |
| 12 | 71: ELSEVIER BIOBASE_1994-2003/Jun W3 |
| 14 | 73: EMBASE_1974-2003/Jun W2 |
| 1 | 94: JICST-EPlus_1985-2003/Jun W3 |
| 3 | 98: General Sci Abs/Full-Text_1984-2003/May |
| 1 | 99: Wilson Appl. Sci & Tech Abs_1983-2003/May |
| 341 | 103: Energy SciTec_1974-2003/May B2 |
| Examined 50 files | |
| 2 | 107: Adis R&D Insight_1986-2003/Jun W2 |
| 65 | 109: Nuclear Sci. Abs._1948-1976 |
| 1 | 111: TGG Natl.Newspaper Index(SM)_1979-2003/Jun 13 |
| 3 | 118: ICONDA-Intl Construction_1976-2003/Jun |
| 1 | 128: PHARMAPROJECTS_1980-2003/Jun W2 |
| 2 | 129: PHIND(Archival)_1980-2003/Jun W2 |
| 5 | 135: NewsRx Weekly Reports_1995-2003/Jun W2 |
| 1 | 143: Biol. & Agric. Index_1983-2003/May |
| 19 | 144: Pascal_1973-2003/Jun W1 |
| 109 | 148: Gale Group Trade & Industry DB_1976-2003/Jun 17 |
| 1 | 149: TGG Health&Wellness DB(SM)_1976-2003/Jun W2 |
| 15 | 155: MEDLINE(R)_1966-2003/Jun W2 |
| 6 | 156: ToxFile_1965-2003/Jun W3 |
| 1 | 158: DIOGENES(R)_1976-2003/Jun W3 |
| 1 | 162: Global Health_1983-2003/May |
| 2 | 172: EMBASE Alert_2003/Jun W3 |
| 10 | 180: Federal Register_1985-2003/Jun 18 |
| 1 | 189: NDA Pipeline: New Drugs_1991-2003/Jun |
| 1 | 203: AGRIS_1974-2003/May |
| 2 | 211: Gale Group Newsearch(TM)_2003/Jun 17 |
| Examined 100 files | |
| 7 | 225: DIALOG(R):Domain Names |
| 3 | 266: FEDRIP_2003/Apr |
| 1 | 275: Gale Group Computer DB(TM)_1983-2003/Jun 18 |
| 1 | 315: ChemEng & Biotec Abs_1970-2003/May |
| 2 | 319: Chem Bus NewsBase_1984-2003/Jun 18 |
| 3 | 340: CLAIMS(R)/US Patent_1950-03/Jun 17 |
| 1 | 342: Derwent Patents Citation Indx_1978-01/200310 |
| 2 | 348: EUROPEAN PATENTS_1978-2003/Jun W01 |
| 24 | 349: PCT FULLTEXT_1979-2002/UB=20030612,UT=20030605 |
| 1 | 357: Derwent Biotech Res._1982-2003/Jun W4 |
| Examined 150 files | |
| 1 | 358: Current BioTech Abs_1983-2003/May |
| 8 | 398: CHEMSEARCH(TM)_1957-2003/MAY |
| 23 | 399: CA SEARCH(R)_1967-2003/UD=13825 |
| 1 | 429: Adis Newsletters(Archive)_1982-2003/Jun 18 |
| 12 | 434: SciSearch(R) Cited Ref Sci_1974-1989/Dec |
| 25 | 440: Current Contents Search(R)_1990-2003/Jun 18 |
| 2 | 441: ESPICOM Pharm&Med DEVICE NEWS_2003/Jun W3 |
| 3 | 445: IMS R&D Focus_1991-2003/Jun W1 |
| 1 | 452: Drug Data Report_1992-2003/May |

1 455: Drug News & Perspectives_1992-2003/May
1 459: Daily Essentials (Archival)_1996-2003/Jun W2

Examined 200 files

232 545: Investext(R)_1982-2003/Jun 18
1 570: Gale Group MARS(R)_1984-2003/Jun 18
2 608: KR/T Bus.News._1992-2003/Jun 18
65 610: Business Wire_1999-2003/Jun 18
7 613: PR Newswire_1999-2003/Jun 18
110 621: Gale Group New Prod.Annou.(R)_1985-2003/Jun 17
9 624: McGraw-Hill Publications_1985-2003/Jun 17
5 635: Business Dateline(R)_1985-2003/Jun 18
20 636: Gale Group Newsletter DB(TM)_1987-2003/Jun 16
2 646: Consumer Reports_1982-2003/May
110 649: Gale Group Newswire ASAP(TM)_2003/Jun 16
12 654: US PAT.FULL._1976-2003/Jun 17

Examined 250 files

2 745: Investext(R) PDF Index_1999--2003/Jun W3
2 761: Datamonitor Market Res._1992-2003/Jun
2 764: BCC Market Research_1989-2003/Jun
32 810: Business Wire_1986-1999/Feb 28
65 813: PR Newswire_1987-1999/Apr 30

80 files have one or more items; file list includes 281 files.

ave temp
p SearchSave "TD270" stored
f
r last SELECT statement was:
S PCRV

| Items | File |
|-------|--|
| 341 | 103: Energy SciTec_1974-2003/May B2 |
| 232 | 545: Investext(R)_1982-2003/Jun 18 |
| 174 | 6: NTIS_1964-2003/Jun W3 |
| 127 | 16: Gale Group PROMT(R)_1990-2003/Jun 18 |
| 110 | 621: Gale Group New Prod.Annou.(R)_1985-2003/Jun 17 |
| 110 | 649: Gale Group Newswire ASAP(TM)_2003/Jun 16 |
| 109 | 148: Gale Group Trade & Industry DB_1976-2003/Jun 17 |
| 105 | 8: Ei Compendex(R)_1970-2003/Jun W2 |
| 88 | 2: INSPEC_1969-2003/Jun W2 |
| 78 | 20: Dialog Global Reporter_1997-2003/Jun 18 |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

p
r last SELECT statement was:
S PCRV

| Items | File |
|-------|---|
| 65 | 109: Nuclear Sci. Abs._1948-1976 |
| 65 | 610: Business Wire_1999-2003/Jun 18 |
| 65 | 813: PR Newswire_1987-1999/Apr 30 |
| 32 | 810: Business Wire_1986-1999/Feb 28 |
| 25 | 440: Current Contents Search(R)_1990-2003/Jun 18 |
| 24 | 349: PCT FULLTEXT_1979-2002/UB=20030612,UT=20030605 |
| 23 | 399: CA SEARCH(R)_1967-2003/UD=13825 |
| 20 | 5: Biosis Previews(R)_1969-2003/Jun W2 |
| 20 | 636: Gale Group Newsletter DB(TM)_1987-2003/Jun 16 |
| 19 | 34: SciSearch(R) Cited Ref Sci_1990-2003/Jun W2 |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

p
r last SELECT statement was:
S PCRV

| Items | File |
|-------|------|
|-------|------|

```

-----
19 144: Pascal_1973-2003/Jun W1
15 155: MEDLINE(R)_1966-2003/Jun W2
14 73: EMBASE_1974-2003/Jun W2
12 71: ELSEVIER BIOBASE_1994-2003/Jun W3
12 434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
12 654: US PAT.FULL._1976-2003/Jun 17
10 180: Federal Register_1985-2003/Jun 18
9 624: McGraw-Hill Publications_1985-2003/Jun 17
8 398: CHEMSEARCH(TM)_1957-2003/MAY
7 225: DIALOG(R):Domain Names

```

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

ur last SELECT statement was:
S PCRV

| Items | File |
|-------|--|
| 7 | 613: PR Newswire_1999-2003/Jun 18 |
| 6 | 156: ToxFile_1965-2003/Jun W3 |
| 5 | 135: NewsRx Weekly Reports_1995-2003/Jun W2 |
| 5 | 635: Business Dateline(R)_1985-2003/Jun 18 |
| 4 | 9: Business & Industry(R)_Jul/1994-2003/Jun 17 |
| 3 | 18: Gale Group F&S Index(R)_1988-2003/Jun 18 |
| 3 | 35: Dissertation Abs Online_1861-2003/May |
| 3 | 63: Transport Res(TRIS)_1970-2003/May |
| 3 | 98: General Sci Abs/Full-Text_1984-2003/May |
| 3 | 118: ICONDA-Intl Construction_1976-2003/Jun |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

ur last SELECT statement was:
S PCRV

| Items | File |
|-------|---|
| 3 | 266: FEDRIP_2003/Apr |
| 3 | 340: CLAIMS(R)/US Patent_1950-03/Jun 17 |
| 3 | 445: IMS R&D Focus_1991-2003/Jun W1 |
| 2 | 19: Chem.Industry Notes_1974-2003/ISS 200324 |
| 2 | 42: Pharmaceuticl News Idx_1974-2003/Jun W2 |
| 2 | 47: Gale Group Magazine DB(TM)_1959-2003/Jun 13 |
| 2 | 107: Adis R&D Insight_1986-2003/Jun W2 |
| 2 | 129: PHIND(Archival)_1980-2003/Jun W2 |
| 2 | 172: EMBASE Alert_2003/Jun W3 |
| 2 | 211: Gale Group Newsearch(TM)_2003/Jun 17 |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

ur last SELECT statement was:
S PCRV

| Items | File |
|-------|--|
| 2 | 319: Chem Bus NewsBase_1984-2003/Jun 18 |
| 2 | 348: EUROPEAN PATENTS_1978-2003/Jun W01 |
| 2 | 441: ESPICOM Pharm&Med DEVICE NEWS_2003/Jun W3 |
| 2 | 608: KR/T Bus.News._1992-2003/Jun 18 |
| 2 | 646: Consumer Reports_1982-2003/May |
| 2 | 745: Investext(R) PDF Index_1999--2003/Jun W3 |
| 2 | 761: Datamonitor Market Res._1992-2003/Jun |
| 2 | 764: BCC Market Research_1989-2003/Jun |
| 1 | 15: ABI/Inform(R)_1971-2003/Jun 18 |
| 1 | 50: CAB Abstracts_1972-2003/May |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

ur last SELECT statement was:
S PCRV

| f | Items | File |
|---|-------|--|
| 1 | 1 | 94: JICST-EPlus_1985-2003/Jun W3 |
| 2 | 1 | 99: Wilson Appl. Sci & Tech Abs_1983-2003/May |
| 3 | 1 | 111: TGG Natl.Newspaper Index(SM)_1979-2003/Jun 13 |
| 4 | 1 | 128: PHARMAPROJECTS_1980-2003/Jun W2 |
| 5 | 1 | 143: Biol. & Agric. Index_1983-2003/May |
| 6 | 1 | 149: TGG Health&Wellness DB(SM)_1976-2003/Jun W2 |
| 7 | 1 | 158: DIOGENES(R)_1976-2003/Jun W3 |
| 8 | 1 | 162: Global Health_1983-2003/May |
| 9 | 1 | 189: NDA Pipeline: New Drugs_1991-2003/Jun |
| 0 | 1 | 203: AGRIS_1974-2003/May |

80 files have one or more items; file list includes 281 files.

- Enter P or PAGE for more -

b n1-n60;exs
18jun03 10:54:02 User228210 Session D348.3
\$2.09 1.043 DialUnits File411
\$2.09 Estimated cost File411
\$0.22 TELNET
\$2.31 Estimated cost this search
\$2.32 Estimated total session cost 1.267 DialUnits

STEM:OS - DIALOG OneSearch

File 103:Energy SciTec 1974-2003/May B2
(c) 2003 Contains copyrighted material
File 103: For access restrictions see Help Restrict.
File 545:Investext(R) 1982-2003/Jun 18
(c) 2003 Thomson Financial Networks
File 6:NTIS 1964-2003/Jun W3
(c) 2003 NTIS, Intl Cpyrght All Rights Res
File 6: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File 16:Gale Group PROMT(R) 1990-2003/Jun 18
(c) 2003 The Gale Group
File 16: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File 621:Gale Group New Prod.Annou.(R) 1985-2003/Jun 17
(c) 2003 The Gale Group
File 649:Gale Group Newswire ASAP(TM) 2003/Jun 16
(c) 2003 The Gale Group
File 148:Gale Group Trade & Industry DB 1976-2003/Jun 17
(c)2003 The Gale Group
File 148: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File 8:Bi Compendex(R) 1970-2003/Jun W2
(c) 2003 Elsevier Eng. Info. Inc.
File 8: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File 2:INSPEC 1969-2003/Jun W2
(c) 2003 Institution of Electrical Engineers
File 2: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File 20:Dialog Global Reporter 1997-2003/Jun 18
(c) 2003 The Dialog Corp.
File 109:Nuclear Sci. Abs. 1948-1976
(c)1997 Contains copyrighted material
File 109: For access restrictions, see HELP RESTRIC1.
File 610:Business Wire 1999-2003/Jun 18
(c) 2003 Business Wire.
File 610: File 610 now contains data from 3/99 forward.
chive data (1986-2/99) is available in File 810.
File 813:PR Newswire 1987-1999/Apr 30

(c) 1999 PR Newswire Association Inc
 File 810:Business Wire 1986-1999/Feb 28
 (c) 1999 Business Wire
 File 440:Current Contents Search(R) 1990-2003/Jun 18
 (c) 2003 Inst for Sci Info
 File 349:PCT FULLTEXT 1979-2002/UB=20030612,UT=20030605
 (c) 2003 WIPO/Univentio
 File 399:CA SEARCH(R) 1967-2003/UD=13825
 (c) 2003 American Chemical Society
 File 399: Use is subject to the terms of your user/customer agreement.
 Alert feature enhanced for multiple files, etc. See HELP ALERT.
 File 5:Biosis Previews(R) 1969-2003/Jun W2
 (c) 2003 BIOSIS
 File 636:Gale Group Newsletter DB(TM) 1987-2003/Jun 16
 (c) 2003 The Gale Group
 File 34:SciSearch(R) Cited Ref Sci 1990-2003/Jun W2
 (c) 2003 Inst for Sci Info
 File 144:Pascal 1973-2003/Jun W1
 (c) 2003 INIST/CNRS
 File 155:MEDLINE(R) 1966-2003/Jun W2
 (c) format only 2003 The Dialog Corp.
 File 155: Medline has been reloaded and accession numbers have
 changed. Please see HELP NEWS 155.
 File 73:EMBASE 1974-2003/Jun W2
 (c) 2003 Elsevier Science B.V.
 File 73: Alert feature enhanced for multiple files, duplicates
 removal, customized scheduling. See HELP ALERT.
 File 71:ELSEVIER BIOBASE 1994-2003/Jun W3
 (c) 2003 Elsevier Science B.V.
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 654:US PAT.FULL. 1976-2003/Jun 17
 (c) FORMAT ONLY 2003 THE DIALOG CORP.
 File 654: Reassignments current through Feb. 7, 2003
 File 180:Federal Register 1985-2003/Jun 18
 (c) 2003 format only The DIALOG Corp
 File 624:McGraw-Hill Publications 1985-2003/Jun 17
 (c) 2003 McGraw-Hill Co. Inc
 File 624: Homeland Security & Defense and 9 Platt energy journals added
 Please see HELP NEWS624 for more
 File 398:CHEMSEARCH(TM) 1957-2003/MAY
 (c) 2003 AMER.CHEM.SOC.
 File 398: Use is subject to the terms of your user/customer agreement.
 Problems with SORT. RANK charge added. See HELP RATES 398.
 File 225:DIALOG(R):Domain Names (c) 2003 Dialog & SnapNames.
 File 225: See HELP NEWS225 for information on changes to search prefixes
 and new display codes
 File 613:PR Newswire 1999-2003/Jun 18
 (c) 2003 PR Newswire Association Inc
 File 613: File 613 now contains data from 5/99 forward.
 Archive data (1987-4/99) is available in File 813.
 File 156:ToxFile 1965-2003/Jun W3
 (c) format only 2003 The Dialog Corporation
 File 156: ToxFile has been reloaded. Accession numbers
 have changed. Please see HELP NEWS 156 for details.
 File 135:NewsRx Weekly Reports 1995-2003/Jun W2
 (c) 2003 NewsRx
 File 135: New newsletters are now added. See Help News135 for the
 complete list of newsletters.
 File 635:Business Dateline(R) 1985-2003/Jun 18
 (c) 2003 ProQuest Info&Learning
 File 9:Business & Industry(R) Jul/1994-2003/Jun 17
 (c) 2003 Resp. DB Svcs.
 File 18:Gale Group F&S Index(R) 1988-2003/Jun 18
 (c) 2003 The Gale Group
 File 35:Dissertation Abs Online 1861-2003/May
 (c) 2003 ProQuest Info&Learning
 File 63:Transport Res(TRIS) 1970-2003/May
 (c) fmt only 2003 Dialog Corp.

File 98:General Sci Abs/Full-Text 1984-2003/May
(c) 2003 The HW Wilson Co.

File 118:ICONDA-Intl Construction 1976-2003/Jun
(c) 2003 Fraunhofer-IRB

File 266:FEDRIP 2003/Apr
Comp & dist by NTIS, Intl Copyright All Rights Res

File 340:CLAIMS(R)/US Patent 1950-03/Jun 17
(c) 2003 IFI/CLAIMS(R)

File 340: The Claims U.S. Patent databases have been reloaded.
HELP NEWS340 & HELP ALERTS340 for search, display & Alert info.

File 445:IMS R&D Focus 1991-2003/Jun W1
(c) 2003 IMS Health & Affiliates

File 19:Chem.Industry Notes 1974-2003/ISS 200324
(c) 2003 Amer.Chem.Soc.

File 19: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 42:Pharmaceutical News Idx 1974-2003/Jun W2
(c)2003 ProQuest Info&Learning

File 47:Gale Group Magazine DB(TM) 1959-2003/Jun 13
(c) 2003 The Gale group

File 107:Adis R&D Insight 1986-2003/Jun W2
(c) 2003 Adis Data Information BV.

File 129:PHIND(Archival) 1980-2003/Jun W2
(c) 2003 PJB Publications, Ltd.

File 172:EMBASE Alert 2003/Jun W3
(c) 2003 Elsevier Science B.V.

File 211:Gale Group Newsearch(TM) 2003/Jun 17
(c) 2003 The Gale Group

File 319:Chem Bus NewsBase 1984-2003/Jun 18
(c) 2003 Elsevier Eng. Info. Inc.

File 319: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.

File 348:EUROPEAN PATENTS 1978-2003/Jun W01
(c) 2003 European Patent Office

File 441:ESPICOM Pharm&Med DEVICE NEWS 2003/Jun W3
(c) 2003 ESPICOM Bus.Intell.

File 608:KR/T Bus.News. 1992-2003/Jun 18
(c)2003 Knight Ridder/Tribune Bus News

File 646:Consumer Reports 1982-2003/May
(c) 2003 Consumer Union

File 745:Investext(R) PDF Index 1999--2003/Jun W3
(c)2003 Thomson Fin. Networks

File 745: INVESTEXT NOW ON DIALOGWEB
ENTER HELP NEWS745 FOR MORE

File 761:Datanomitor Market Res. 1992-2003/Jun
(c) 2003 Datanomitor

File 764:BCC Market Research 1989-2003/Jun
(c) 2003 Business Communication Co.

File 764: KWIC costs \$3.30 in File 764.

File 15:ABI/Inform(R) 1971-2003/Jun 18
(c) 2003 ProQuest Info&Learning

File 15: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.

File 50:CAB Abstracts 1972-2003/May
(c) 2003 CAB International

File 50: Truncating CC codes is recommended for full retrieval.
See Help News50 for details.

| Set | Items | Description |
|-----|-------|-------------|
| --- | ----- | ----- |

Truncating TD270

Light option is not available in file(s) 19, 109, 398, 399
LIGHT set on as '%'

S1 2033 PCRV
s s1 and pseudomonas

2033 S1
520782 PSEUDOMONAS

S2 223 S1 AND PSEUDOMONAS
s s2 and protein

223 S2
 11062652 PROTEIN
 S3 175 S2 AND PROTEIN
 S3 and antibody or antibodies
 essing
 essed 20 of 60 files ...
 eted processing all files
 175 S3
 2445490 ANTIBODY
 2287070 ANTIBODIES
 S4 2287108 S3 AND ANTIBODY OR ANTIBODIES
 S4 and S3
 2287108 S4
 175 S3
 S5 122 S4 AND S3

Duplicate detection is not supported for File 349.
 Duplicate detection is not supported for File 654.
 Duplicate detection is not supported for File 398.
 Duplicate detection is not supported for File 225.
 Duplicate detection is not supported for File 340.
 Duplicate detection is not supported for File 19.
 Duplicate detection is not supported for File 107.
 Duplicate detection is not supported for File 348.
 Duplicate detection is not supported for File 441.
 Duplicate detection is not supported for File 761.
 Duplicate detection is not supported for File 764.

Records from unsupported files will be retained in the RD set.
 Record 440:15927493 ignored; incomplete bibliographic data, not retained
 RD set
 Record 440:13242482 ignored; incomplete bibliographic data, not retained
 RD set
 Record 440:12995370 ignored; incomplete bibliographic data, not retained
 RD set
 examined 50 records (50)
 examined 50 records (100)
 Record 441:34236 ignored; incomplete bibliographic data, not retained in
 RD set
 Record 441:32012 ignored; incomplete bibliographic data, not retained in
 RD set
 completed examining records
 S6 61 RD (unique items)

| Items | Description |
|---------|-------------------------------|
| 2033 | PCRV |
| 223 | S1 AND PSEUDOMONAS |
| 175 | S2 AND PROTEIN |
| 2287108 | S3 AND ANTIBODY OR ANTIBODIES |
| 122 | S4 AND S3 |
| 61 | RD (unique items) |

t s6/3,ab/1-30
 >No matching display code(s) found in file(s): 107, 129, 135, 180, 225,
 398, 441, 608, 624, 635, 761, 764, 810, 813

s/3,AB/1 (Item 1 from file: 545)
 ALLOG(R)File 545:Investext(R)
 c) 2003 Thomson Financial Networks . All rts. reserv.

1587808
 INTERMUNE PHARMACEUTICALS
 EHENY, A.R.
 EW YORK (STATE OF)
 EHMAN BROTHERS, INC. (DATE: February 21, 01) (Report Number: 2480630)PAGE
 OF 3, TEXT PAGE
 This is a(n) COMPANY report.

,AB/2 (Item 2 from file: 545)
OG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

9462
TEIN% DESIGN LABS
EK, J.D.
YORK (STATE OF)
RD FRERES & COMPANY, LLC (DATE: November 29, 00) (Report Number:
C4C)PAGE 1 OF 2. TEXT/TABLE PAGE
s is a(n) COMPANY report.

,AB/3 (Item 3 from file: 545)
OG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

33939
TEIN% DESIGN LABS/INTERMUNE
D, M.
YORK (STATE OF)
MAN BROTHERS, INC. (DATE: November 29, 00) (Report Number: 2384611)PAGE
F 2, TEXT PAGE
s is a(n) COMPANY report.

,AB/4 (Item 4 from file: 545)
OG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

21331
ERMUNE PHARMACEUTICALS: INITIATING COVERAGE
ENY, A.R.
YORK (STATE OF)
MAN BROTHERS, INC. (DATE: August 2, 00) (Report Number: 2243254)PAGE 7
15, TEXT PAGE
s is a(n) COMPANY report.

,AB/5 (Item 5 from file: 545)
OG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

744719
TERMUNE PHARMACEUTICALS
LLOY, M.
W YORK (STATE OF)
ASE HAMBRECHT & QUIST INC. (DATE: June 13, 00) (Report Number: 2192983)
GE 10 OF 16, TEXT PAGE
is is a(n) COMPANY report.

/3,AB/6 (Item 1 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
) 2003 The Gale Group. All rts. reserv.

282537 Supplier Number: 80767850
terMune Announces Five Abstracts to Be Presented at ICAAC Annual Meeting
Highlighting Infectious Disease Pipeline; Phase III Oritavancin Results
in CSSI and Phase II Actimmune Results in Fungal Infections to Be
Presented as Late-Breakers.
Newswire, pSFT02613122001
c 13, 2001
anguage: English Record Type: Fulltext
cument Type: Newswire; Trade
rd Count: 810

/3,AB/7 (Item 2 from file: 16)

LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

2686 Supplier Number: 79398132
rMune Announces Third Quarter 2001 Financial Results.
ewswire, pNA
24, 2001
uage: English Record Type: Fulltext
ment Type: Newswire; Trade
Count: 1421

,AB/8 (Item 3 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

59452 Supplier Number: 79083290
erMune Carries Forward Work On MAb Compound.
& Outbreaks Week, pNA
2, 2001
uage: English Record Type: Fulltext
ment Type: Newsletter; Professional
d Count: 454

3,AB/9 (Item 4 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

61634 Supplier Number: 79023138
tibody% Drug for %Pseudomonas% Infection.
lied Genetics News, v22, n2, pNA
t, 2001
uage: English Record Type: Fulltext
ment Type: Newsletter; Trade
d Count: 429

/3,AB/10 (Item 5 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

951655 Supplier Number: 77710441
terMune accepts %antibody% from %Protein% Design Labs. (Brief Article)
rketletter, pNA
pt 3, 2001
uage: English Record Type: Fulltext
ticle Type: Brief Article
cument Type: Newsletter; Trade
rd Count: 78

/3,AB/11 (Item 6 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

931960 Supplier Number: 77480563
ab, %Pseudomonas% aeruginosa, InterMune InterMune, %Protein% Design
receives humanized MAb. (Brief Article)
& D Focus Drug News, pNA
ugust 27, 2001
uage: English Record Type: Fulltext
rticle Type: Brief Article
ocument Type: Magazine/Journal; Trade
ord Count: 114

6/3,AB/12 (Item 7 from file: 16)
IALOG(R)File 16:Gale Group PROMT(R)

003 The Gale Group. All rts. reserv.

301 Supplier Number: 77245082
Mune to Develop Compound for the Treatment and Prevention of
eudomonas% Infections.
wswire, p0834
t 16, 2001
age: English Record Type: Fulltext
ment Type: Newswire; Trade
Count: 797

AB/13 (Item 8 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

6245 Supplier Number: 68016518
%Pseudomonas% aeruginosa, InterMune InterMune, %Protein% Design
censing agreement.
D Focus Drug News, pNA
18, 2000
uage: English Record Type: Fulltext
ment Type: Magazine/Journal; Trade
Count: 137

,AB/14 (Item 9 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

91204 Supplier Number: 67460930
rotein% Design Labs and InterMune Announce %Antibody% Humanization
greement.
Newswire, pNA
28, 2000
uage: English Record Type: Fulltext
ument Type: Newswire; Trade
d Count: 563

3,AB/15 (Item 10 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

960444 Supplier Number: 66520548
eventing %Pseudomonas%- Induced Pneumonia.
plied Genetics News, v21, n3, pNA
c, 2000
uage: English Record Type: Fulltext
ument Type: Newsletter; Trade
rd Count: 280

/3,AB/16 (Item 11 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
) 2003 The Gale Group. All rts. reserv.

812514 Supplier Number: 65268780
AAC Abstract Reports Therapy With %Antibody% To %PcrV% Effective Against
%Pseudomonas% Aeruginosa Pneumonia.
usiness Wire, p2081
ept 18, 2000
uage: English Record Type: Fulltext
ocument Type: Newswire; Trade
ord Count: 659

5/3,AB/17 (Item 12 from file: 16)
IALOG(R)File 16:Gale Group PROMT(R)

ilwaukee, WI 53202, US,
t and Priority Information (Country, Number, Date):
ent: WO 200264161 A2-A3 20020822 (WO 0264161)
lication: WO 2002US2382 20020125 (PCT/WO US0202382)
riority Application: US 2001770916 20010126; US 2001264795 20010129
nated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
p) AT BE CH CY DE DK ES FI FR GB GR IE IT LJ MC NL PT SE TR
a) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
p) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
a) AM AZ BY KG KZ MD RU TJ TM
ication Language: English
ng Language: English
text Word Count: 10010

ish Abstract
method of inhibiting, moderating or diagnosing %Pseudomonas% aeruginosa
fection is disclosed. In one embodiment, this method comprises
oculating a patient with an effective amount of %PcrV% antigen.

ch Abstract
invention concerne un procede d'inhibition, de moderation ou de
agnostic d'infection a %Pseudomonas% aeruginosa. Dans une realisation,
procede consiste a inoculer un patient avec une quantite efficace
antigene %PcrV%.

,AB/22 (Item 2 from file: 349)
OG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

29955
CINE COMPOSITION
POSITION VACCINALE
ent Applicant/Assignee:
MITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330
Rixensart, BE, BE (Residence), BE (Nationality), (For all designated
states except: US)
ent Applicant/Inventor:
ERTHET Francois-Xavier Jacques, GlaxoSmithKline Biologicals S.A., Rue de
l'Institute 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
OBET Yves, GlaxoSmithKline Biologicals S.A., Rue de l'Institute 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
POOLMAN Jan, GlaxoSmithKline Biologicals S.A., Rue de l'Institute 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
VERLANT Vincent Georges Christian Louis, GlaxoSmithKline Biologicals
S.A., Rue de l'Institute 89, B-1330 Rixensart, BE, BE (Residence), BE
(Nationality), (Designated only for: US)
gal Representative:
LUBIENSKI Michael John (agent), GlaxoSmithKline CN925.1, Corporate
Intellectual Property, 980 Great West Road, Brentford, Middlesex TW8
9GS, GB,

ent and Priority Information (Country, Number, Date):
Patent: WO 200262380 A2 20020815 (WO 0262380)
Application: WO 2002EP1356 20020208 (PCT/WO EP0201356)
Priority Application: GB 20013169 20010208
signed States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

cation Language: English
g Language: English
ext Word Count: 13939

sh Abstract

The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed Chlamydia antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.

ch Abstract

L'invention concerne des compositions vaccinales a base de bacteries a gram negatif, leur preparation, ainsi que leur utilisation en medecine. Plus particulierement, l'invention concerne des compositions utiles de vesicules de membranes externes (bleb) de bacteries a gram negatif presentant une expression d'antigenes deChlamydia heterologues, ainsi que des methodes avantageuses permettant de rendre ces compositions plus efficaces et plus sures comme vaccins.

3,AB/23 (Item 3 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

29953

ERBLEBBING BACTERIAL STRAINS AND USE THEREOF FOR PRODUCTION OF VACCINES POSITION DE VACCIN

ent Applicant/Assignee:

MITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (For all designated states except: US)

ent Applicant/Inventor:

BERTHET Francois-Xavier Jacques, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality), (Designated only for: US)

DENOEL Philippe, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

NEYT Cecile Anne, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

POOLMAN Jan, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), NL (Nationality), (Designated only for: US)

THONNARD Joelle, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

gal Representative:

LUBIENSKI Michael John (agent), Corporate Intellectual Property, GlaxoSmithKline Beecham CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS, GB,

atent and Priority Information (Country, Number, Date):

Patent: WO 200262378 A2-A3 20020815 (WO 0262378)

Application: WO 2002EP1361 20020208 (PCT/WO EP0201361)

Priority Application: GB 20013171 20010208

esignated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR (OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

ublication Language: English

iling Language: English

ulltext Word Count: 14322

ish Abstract

The present invention relates to the field genetically-engineered Gram-negative bacterial strains that have improved outer-membrane vesicle budding properties, and vaccine compositions comprising these bacteria or vesicles. The present invention provides a hyperbledding Gram-negative bacterium which has been genetically modified by either or both processes selected from a group of consisting of: down-regulation of expression of one or more tol genes; and mutation of one or more gene(s) encoding a protein% comprising a peptidoglycan-associated site to attenuate the peptidoglycan binding activity of the %protein%(s).

nch Abstract

La presente invention concerne le domaine des nouvelles souches de bacteries Gram negatif fabriquees qui presentent des proprietes ameliores d'elimination des vesicules de la membrane exterieure et des compositions de vaccin comprenant ces bacteries ou ces vesicules. Cette invention concerne une bacterie gram negatif hyperboursoufflee qui a ete genetiquement modifiee par un et/ou deux processus tels que: la regulation restrictive de l'expression d'au moins un gene <i>tol</i>; et la mutation d'au moins un gene codant une proteine comprenant un site associe au peptidoglycane pour attenuer l'activite de liaison avec le peptidoglycane de la (des) proteine(s).

3,AB/24 (Item 4 from file: 349)
LOG(R) File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

377369

VACCINES COMPRISING OUTER MEMBRANE VESICLES FROM GRAM NEGATIVE BACTERIA
COMPOSITION VACCINALE

Agent Applicant/Assignee:

GLAXOSMITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (For all designated states except: US)

Agent Applicant/Inventor:

BERTHET Francois-Xavier Jacques, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality), (Designated only for: US)

DALEMANS Wilfried, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

DENOEL Philippe, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

DEQUESNE Guy, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

FERON Christiane, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

GARCON Nathalie, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality), (Designated only for: US)

LOBET Yves, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

POOLMAN Jan, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), NL (Nationality), (Designated only for: US)

THIRY Georges, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

THONNARD Joelle, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

VOET Pierre, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

Legal Representative:

UBIENSKI Michael John (agent), SmithKline Beecham, Corporate
Intellectual Property (CN9.25.1), 980 Great West Road, Brentford,
Middlesex TW8 9GS, GB,

Agent and Priority Information (Country, Number, Date):

Patent: WO 200209746 A2-A3 20020207 (WO 0209746)

Application: WO 2001EP8857 20010731 (PCT/WO EP0108857)

Priority Application: WO 2000EP7424 20000731; GB 20013170 20010208

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD

SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Claiming Language: English

Fulltext Word Count: 32856

English Abstract

The present invention relates to the field of vaccine formulation,
particularly the field of novel adjuvant compositions comprising outer
membrane vesicles (or blebs), and advantageous methods of detoxifying
these compositions, and advantageous methods of use of such adjuvants.

French Abstract

Cette invention, qui a trait au domaine de la formulation vaccinale,
notamment a de nouvelles compositions d'adjuvant comportant des vesicule
a membrane externe (ou bulles), concerne egalement des methodes
permettant de detoxiquer avantageusement ces compositions ainsi que des
methodes d'utilisation avantageuse des adjuvants susmentionnes.

/3,AB/25 (Item 5 from file: 349)

ALOG(R) File 349:PCT FULLTEXT

) 2003 WIPO/Univentio. All rts. reserv.

804134

COMBINANT CHLAMYDIA VACCINE

CCINS RECOMBINES CONTRE LES CHLAMYDIA

Agent Applicant/Assignee:

MICHIGAN STATE UNIVERSITY, 238 Administration Building, East Lansing, MI
48824, US, US (Residence), US (Nationality)

Inventor(s):

BRUBAKER Robert R, 11042 W. Scipio Highway, Vermontville, MI 49096, US,

MOTIN Vladimir L, 5621 Charlotte Way, #17, Livermore, CA 94550, US,

Legal Representative:

McLEOD Ian C (agent), 2190 Commons Parkway, Okemos, MI 48864, US,

Agent and Priority Information (Country, Number, Date):

Patent: WO 200135992 A1 20010525 (WO 0135992)

Application: WO 2000US30876 20001110 (PCT/WO US0030876)

Priority Application: US 99444425 19991119

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Claiming Language: English

Fulltext Word Count: 14526

English Abstract

The present invention provides vaccines and methods for making the
vaccines that actively or passively protect a human or animal against
Chlamydia infection. In particular, the present invention provides a

ccine that provides active immunity, which comprises a polypeptide of
A vaccine that contains or expresses at least one epitope of
lypeptide that has an amino acid sequence that is substantially similar
an amino acid sequence of a polypeptide encoded by open reading frame
863 of Chlamydia trachomatis. The present invention further provides a
ccine that provides passive immunity to Chlamydia comprising polyclonal
monoclonal antibodies against at least one epitope of a polypeptide
coded by open reading frame CT863 of Chlamydia trachomatis. Further
ill, the present invention provides a method for preventing an
inflammatory reaction, in particular, in a skin graft, by providing a
lypeptide that is substantially similar to a polypeptide encoded by
open reading frame CT863 of Chlamydia trachomatis.

French Abstract

La presente invention concerne des vaccins et des methodes de production
des vaccins protegeant activement ou passivement un sujet humain ou
animal contre une infection a Chlamydia. En particulier, la presente
invention concerne un vaccin procurant une immunité active qui comprend
un vaccin polypeptidique ou a ADN contenant ou exprimant au moins un
epitope de polypeptide presentant une sequence d'acides amines
sensiblement similaire a une sequence d'acides amines d'un polypeptide
code par un cadre de lecture ouvert CT863 de Chlamydia trachomatis. La
presente invention concerne egalement un vaccin procurant une immunité
passive contre les Chlamydia et comprenant des anticorps polyclonaux ou
monoclonaux contre au moins un epitope d'un polypeptide code par le cadre
de lecture ouvert CT863 de Chlamydia trachomatis. De plus, la presente
invention concerne une methode de prevention d'une réaction
inflammatoire, en particulier, dans une greffe de peau, par l'obtention
d'un polypeptide sensiblement similaire a un polypeptide code par le
cadre de lecture ouvert CT863 de Chlamydia trachomatis.

3,AB/26 (Item 6 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

76938

GENETICALLY ENGINEERED BLEB VACCINE POSITION DE VACCIN

Agent Applicant/Assignee:

SMITHKLINE BEECHAM BIOLOGICALS S A, 89, rue de l'Institut, B-1330
Rixensart, BE, BE (Residence), BE (Nationality), (For all designated
states except: US)

Agent Applicant/Inventor:

BERTHET Francois-Xavier Jacques, SmithKline Beecham Biologicals s.a., 89,
rue de l'Institut, B-1330 Rixensart, BE, BE (Residence), FR
(Nationality), (Designated only for: US)

DALEMANS Wilfried L J, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)

DENOEL Philippe, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)

DEQUESNE Guy, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)

FERON Christiane, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)

LOBET Yves, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)

POOLMAN Jan, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, NL (Residence), NL (Nationality), (Designated
only for: US)

THIRY Georges, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)

THONNARD Joelle, SmithKline Beecham Biologicals s.a., 89, rue de

l'Institut, B-1330 Rixensart, BE, (Residence), BE (Nationality),
(Designated only for: US)
ET Pierre, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)

l Representative:
LTON Marcus Jonathan William (agent), Corporate Intellectual Property,
SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8

9EP, GB,
nt and Priority Information (Country, Number, Date):
tent: WO 200109350 A2-A3 20010208 (WO 0109350)

plication: WO 2000EP7424 20000731 (PCT/WO EP0007424)

riority Application: GB 9918319 19990803

gnated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG

SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

EA) AM AZ BY KG KZ MD RU TJ TM

lication Language: English

ing Language: English

text Word Count: 33458

lish Abstract

ne present invention relates to an immuno-protective and non-toxic
ram-negative bleb vaccine suitable for paediatric use. Examples of the
ram-negative strains from which the blebs are made are N. meningitidis,
. catarrhalis and H. influenzae. The blebs of the invention are improved
y one or more genetic changes to the chromosome of the bacterium,
ncluding up-regulation of protective antigens, down-regulation of
mmunodominant non-protective antigens, and detoxification of the Lipid A
oiety of LPS.

nch Abstract

'invention concerne un vaccin immunoprotecteur et non toxique produit a
partir des bulles de la membrane externe (<= bleb >=), convenant pour les
applications pediatriques. Les souches gram-negatives produisant ces
bulles comprennent par exemple N. meningitidis, M. catarrhalis et H.
nfluenzae. Ces vaccins sont ameliores au moyen d'une ou de plusieurs
modifications genetiques du chromosome de la bacterie, ces modifications
produisant notamment une regulation positive des antigenes protecteurs et
une regulation negative des antigenes non protecteurs immunodominants,
ainsi qu'une detoxication de la portion lipidique A des LPS.

/3,AB/27 (Item 7 from file: 349)

ALOG(R)File 349:PCT FULLTEXT

) 2003 WIPO/Univentio. All rts. reserv.

764867

HUMAN SECRETED PROTEINS
PROTEINES SECRETEES HUMAINES

tent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

tent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)

KOMATSOU LIS George A, 9518 Garwood Street, Silver Spring, MD 20901, US,
US (Residence), US (Nationality), (Designated only for: US)

egal Representative:

HOOVER Kenley K (et al) (agent), Human Genome Sciences, Inc., 9410 Key
West Avenue, Rockville, MD 20850, US,

ntent and Priority Information (Country, Number, Date):

cent: WO 200077026 A 20001221 (WO 0077026)
plication: WO 2000US14973 20000601 (PCT/WO US0014973)
riority Application: US 99138630 19990611
gnated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TR TT TZ UA UG US UZ VN YU ZA ZW
P) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
A) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
P) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
A) AM AZ BY KG KZ MD RU TJ TM
ication Language: English
ng Language: English
text Word Count: 153279

ish Abstract
ne present invention relates to novel human secreted proteins and
isolated nucleic acids containing the coding regions of the genes
ncoding such proteins. Also provided are vectors, host cells,
antibodies, and recombinant methods for producing human secreted
roteins. The invention further relates to diagnostic and therapeutic
ethods useful for diagnosing and treating diseases, disorders, and/or
onditions related to these novel human secreted proteins.

nch Abstract
ette invention se rapporte a de nouvelles proteines secretees humaines
t a des acides nucleiques isolés contenant les regions de codage des
enes codant ces proteines. Cette invention se rapporte également a des
ecteurs, des cellules hotes, des anticorps et des procedes de
ecombinaison permettant de produire des proteines secretees humaines;
insi qu'a des procedes diagnostiques et therapeutiques servant a
iagnostiquer et a traiter des maladies, des troubles et/ou des etats
ies a ces nouvelles proteines secretees humaines.

3,AB/28 (Item 8 from file: 349)
ALOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

761296
TIVATION OF DENDRITIC CELLS TO ENHANCE IMMUNITY
TIVATION DE CELLULES DENDRITIQUES POUR ACCROITRE L'IMMUNITE
tent Applicant/Assignee:
CORNELL RESEARCH FOUNDATION INC, Cornell Business & Technology Park, 20
Thornwood Drive, Suite 105, Ithaca, NY 14850, US, US (Residence), US
(Nationality)

ventor(s):
CRYSTAL Ronald G, 1300 York Avenue, Box 96, New York, NY 10021, US,
KIKUCHI Toshiaki, 1300 York Avenue, Box F 401, New York, NY 10021, US,
FUSHIMI Toshiaki, 1300 York Avenue, Box F 401, New York, NY 10021, US,

egal Representative:
LARCHER Carol (et al) (agent), Leydig, Voit & Mayer, Ltd., Suite 4900,
Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780, US,

tent and Priority Information (Country, Number, Date):

Patent: WO 200073432 A2-A3 20001207 (WO 0073432)
Application: WO 2000US15308 20000601 (PCT/WO US0015308)

Priority Application: US 99137042 19990601
esignated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

ublication Language: English

iling Language: English

ulltext Word Count: 20171

English Abstract
The present invention provides a method of enhancing immunity in a mammal. The method comprises modifying a dendritic cell (DC) in vivo or ex vivo to produce a dendritic cell-mediator in the mammal. The dendritic cell-mediator up-regulates DC in the mammal, thereby enhancing immunity in the mammal. The present invention further provides a method of inducing an immune response to an antigen, cancer, or infectious disease in a mammal. In one embodiment, the method comprises administering the antigen or an antigen of the cancer or infectious disease to a mammal, which has been treated as described above, whereupon an immune response to the antigen, cancer, or infectious disease, respectively, is induced in the mammal. In another embodiment, the method comprises administering DC to a mammal as described above, however, the method further comprises contacting the DC, which has been modified to produce a dendritic cell-mediator, with the antigen or an antigen of the cancer or infectious disease prior to administration of the DC to the mammal, whereupon an immune response to the antigen, cancer or infectious disease, respectively, is induced in the mammal.

French Abstract
La presente invention concerne un procede permettant d'accroître l'immunité chez un mammifère. Ce procede consiste a modifier une cellule dendritique (CD) in vivo ou ex vivo, et ce afin de produire chez le mammifère un mediateur des cellules dendritiques. Ce mediateur des cellules dendritiques regule positivement les CD du mammifère, stimulant ainsi son systeme immunitaire. L'invention concerne egalement un procede permettant d'induire chez un mammifère une reponse immunitaire a un antigene, au cancer ou a une maladie infectieuse. Dans un mode de realisation, le procede consiste a administrer l'antigene ou un antigene du cancer ou de la maladie infectieuse a un mammifère ayant ete traite comme decrit ci-dessus, ce qui a pour effet d'induire une reponse immunitaire respectivement a l'antigene, au cancer ou a la maladie infectieuse. Dans un autre mode de realisation, le procede consiste a administrer a un mammifère une CD d'apres la description ci-dessus. Toutefois, le procede consiste egalement a mettre en contact la CD, préalablement modifiée pour produire un mediateur des cellules dendritiques, avec l'antigene ou un antigene du cancer ou de la maladie infectieuse, avant d'administrer la CD au mammifère, ce qui induit une reponse immunitaire respectivement a l'antigene, au cancer ou a la maladie infectieuse.

/3,AB/29 (Item 9 from file: 349)
ALOG(R) File 349:PCT FULLTEXT
© 2003 WIPO/Univentio. All rts. reserv.

570499
METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE i(%PSEUDOMONAS%) V
ANTIGEN
PROCEDURE ET COMPOSITION POUR UNE IMMUNISATION AVEC L'ANTIGENE i(
%PSEUDOMONAS%) V
Patent Applicant/Assignee:
MCW RESEARCH FOUNDATION INC,
Inventor(s):
FRANK Dara W,
YAHN Timothy L,
SAWA Teiji,
WIENER-KRONISH Jeanine,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200033872 A2 20000615 (WO 0033872)
Application: WO 99US27796 19991123 (PCT/WO US9927796)
Priority Application: US 98109952 19981125; US 99126794 19990330
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM
EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG UZ VN YU ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GN GW ML MR NE SN TD TG
Publication Language: English

ltext Word Count: 7504

lish Abstract

method of inhibiting, moderating or diagnosing i(Pseudomonas aeruginosa) infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of %PcrV% antigen.

nch Abstract

'invention concerne un procede destine a bloquer, ralentir ou diagnostiquer une infection par i(%Pseudomonas% aeruginosa). Dans un des modes operatoires, on injecte au patient une dose efficace d'antigene PcrV%.

3,AB/30 (Item 10 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

07974

EROMONE COMPOSITIONS AND METHODS OF USE IN CONTROLLING FUNGAL DISEASES IN PLANTS

POSITIONS PHEROMONALES ET LEURS PROCEDES D'UTILISATION POUR LA LUTTE CONTRE LES MALADIES FONGIQUES DANS LES PLANTES

ent Applicant/Assignee:

THE TEXAS A & M UNIVERSITY SYSTEM,

VAN ALFEN Neal J,

EBBOLE Daniel J,

BECKERMAN Janna L,

ZHANG Lei,

MCCABE Patricia,

KAZMIERCZAK Pam,

ventor(s):

VAN ALFEN Neal J,

EBBOLE Daniel J,

BECKERMAN Janna L,

ZHANG Lei,

MCCABE Patricia,

KAZMIERCZAK Pam,

ent and Priority Information (Country, Number, Date):

Patent: WO 9748719 A1 19971224

Application: WO 97US10364 19970617 (PCT/WO US9710364)

Priority Application: US 9619598 19960617

signed States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN

MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU

ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES

FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD

TG

blication Language: English

ltext Word Count: 44290

glish Abstract

Disclosed are pheromone compositions comprising fungal mating factors, methods for making and using native and recombinant pheromone compositions and derivatives thereof in interfering with fungal pathogenesis, and methods for making and using these compositions for preventing fungal infection and disease in plants.

nch Abstract

L'invention concerne des compositions de pheromonales comprenant des facteurs d'appariement fongique, des procedes de fabrication et d'utilisation de compositions pheromonales natives et recombinées et leurs derives pour empecher la pathogenese fongique et des procedes de fabrication et d'utilisation de ces compositions pour prevenir l'infection fongique et les maladies dans les plantes.

| Items | Description |
|---------|-------------------------------|
| 2033 | PCRV |
| 223 | S1 AND PSEUDOMONAS |
| 175 | S2 AND PROTEIN |
| 2287108 | S3 AND ANTIBODY OR ANTIBODIES |
| 122 | S4 AND S3 |
| 61 | RD (unique items) |

s6/3,ab/31-61
 No matching display code(s) found in file(s): 107, 129, 135, 180, 225,
 398, 441, 608, 624, 635, 761, 764, 810, 813

3,AB/31 (Item 11 from file: 349)
 LOG(R)File 349:PCT FULLTEXT
 2003 WIPO/Univentio. All rts. reserv.

86558
 ORIN BINDING %PROTEIN% COMPOSITIONS AND METHODS OF USE
 POSITIONS DE PROTEINES DE LIAISON DE LA DECORINE ET MODES D'UTILISATION

ent Applicant/Assignee:

HE TEXAS A & M UNIVERSITY SYSTEM,
 EDIMMUNE INCORPORATED,

UO Betty P,

ook Magnus,

ANSON Mark,

entor(s):

UO Betty P,

ook Magnus,

ANSON Mark,

ent and Priority Information (Country, Number, Date):

Patent: WO 9727301 A1 19970731

Application: WO 96US17081 19961022 (PCT/WO US9617081)

Priority Application: US 96589711 19960122; WO 96US5886 19960424

esignated States: AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI

BB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX

NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN KE LS MW

SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT

LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

olication Language: English

lltext Word Count: 66294

glish Abstract

Disclosed are the dbp gene and dbp-derived nucleic acid segments from
 Borrelia burgdorferi, the etiological agent of Lyme disease, and DNA
 segments encoding dbp from related borrelias. Also disclosed are decorin
 binding %protein% compositions and methods of use. The DBP %protein% and
 antigenic epitopes derived therefrom are contemplated for use in the
 treatment of pathological Borrelia infections, and in particular, for use
 in the prevention of bacterial adhesion to decorin. DNA segments encoding
 these proteins and anti-(decorin binding %protein%) %antibodies% will
 also be of use in various screening, diagnostic and therapeutic
 applications including active and passive immunization and methods for
 the prevention of Borrelia colonization in an animal. These DNA segments
 and the peptides derived therefrom are contemplated for use in the
 preparation of vaccines and, also, for use as carrier proteins in vaccine
 formulations, and in the formulation of compositions for use in the
 prevention of Lyme disease.

rench Abstract

L'invention concerne le gene dbp et des segments d'acide nucleique
 derives de la dbp provenant de Borrelia burgdorferi, agent etologique de
 la maladie de Lyme, ainsi que des segments d'ADN codant pour la dbp
 provenant de borrelias voisines. Elle concerne egalement des compositions
 de proteines de liaison de la decorine et leurs modes d'utilisation. Il
 est propose d'utiliser la proteine DBP, ainsi que les epitopes
 antigeniques qui en sont derives, pour le traitement des infections
 pathologiques a Borrelia et notamment pour la prevention de l'adhesion
 bacterienne a la decorine. Les segments d'ADN codant pour ces proteines
 et les anticorps anti-(proteine de liaison de la decorine) peuvent
 egalement etre utilises pour diverses applications de criblage, de

inventor: Frank, Dara W., West Allis, WI
Yahr, Timothy L., Hanover, NH
Sawa, Teiji, San Francisco, CA
Wiener-Kronish, Jeanine, San Francisco, CA
assignee: MCW Research Foundation (02), Milwaukee, WI
The Regents of the University of California (02), Oakland, CA
California, University of Regents
Mcw Research Foundation Inc (Code: 13234 18617)
inventor: Graser, Jennifer E. (Art Unit: 165)
Firm: Quarles & Brady LLP

| | Publication Number | Kind | Date | Application Number | Filing Date |
|--------|-----------------------|------|----------|-----------------------|----------------|
| Patent | US 6309651 | A | 20011030 | US 99448339 | 19991123 |

Fulltext Word Count: 6880

Abstract:
A method of inhibiting, moderating or diagnosing *Pseudomonas aeruginosa* infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of *PcrV* antigen.

3,AB/42 (Item 1 from file: 613)
ALOG(R)File 613:PR Newswire
2003 PR Newswire Association Inc. All rts. reserv.

589862 20011213SFTH026
Mune Announces Five Abstracts to Be Presented
Newswire
Thursday, December 13, 2001 06:01 EST
JRNAL CODE: PR LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT
DOCUMENT TYPE: NEWSWIRE
RD COUNT: 934

3,AB/43 (Item 1 from file: 156)
ALOG(R)File 156:ToxFile
) format only 2003 The Dialog Corporation. All rts. reserv.

904037 NLM Doc No: CRISP/2000/HL59239-03 Sec. Source ID:
ISP/2000/HL59239-03
THE HOST RESPONSE TO CYTOTOXIC PROTEINS
WIENER-KRONISH JP
UNIV. OF CALIFORNIA, SAN FRANCISCO, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO,
CALIFORNIA 941
Source: Crisp Data Base National Institutes of Health
City or State: CALIFORNIA Zip Code: 941
Pub. Year: 2000
Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH
SERVICE; NATIONAL INSTITUTES OF HEALTH, NATIONAL HEART, LUNG, AND BLOOD
INSTITUTE
Award Type: Grant
Document type: Research
Languages: ENGLISH
Record type: Completed
High mortality rates are associated with nosocomial lung infections due
to *P. aeruginosa*. As current antibiotic therapies are associated with a
50-80 percent mortality in this infection, improved methods for prevention
and therapy clearly are needed. The airspace instillation of PA103, a
cytotoxic strain of *P. aeruginosa*, recreates the lung injury and sepsis seen
in many of the patients with nosocomial pneumonia; the instillation of the
bacteria causes lung epithelial injury, bacteremia, organ failure and death
in experimental animals. Over the last 4 years, our two laboratories have
collaborated on bacterial genetic experiments and animal physiology
experiments that have led to the discovery of novel *P. aeruginosa*

the type III secretory system. Our previous investigations have documented that lung injury and dissemination of the airspace PA103 to the circulation are related with the production of exoenzyme S by the bacteria. Two of the bacterial extracellular products produced and secreted with exoenzyme S are ExoU, a novel cytotoxin, and %PcrV%, a homolog of the Yersinia pestis V antigen, which may affect host cytokine production. Our hypothesis is that these two bacterial products are the major virulence products of P.aeruginosa and therapies directed against these products would prevent local and systemic injury due to the dissemination seen with this infection. To prove this hypothesis, we will compare the effects of these newly discovered bacterial products to P.aeruginosa endotoxin in terms of their individual and combined effects on lung injury, lung inflammation and systemic inflammatory response. We will utilize isogenic transposon 103 strains that are selectively missing the genes for ExoU, for %PcrV% and both of these genes. These 2 recombinant proteins are also available for experiments and we have obtained specific endotoxin antagonists and genetically deficient mice for lipopolysaccharide binding %protein% to determine the effects of these products in animals resistant to the effects of endotoxin. We will determine whether these two bacterial products are responsible for IL-10 production in vivo and if blockade of the IL-10 improves local host defense.

13,AB/50 (Item 3 from file: 266)

ALOG(R)File 266:FEDRIP

up & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

297072

IDENTIFYING NO.: 5R01AI44101-04 AGENCY CODE: CRISP

BIOLOGY OF %PCRV%

PRINCIPAL INVESTIGATOR: WIENER-KRONISH, JEANINE P.

ADDRESS: WIENERKJ@ANESTHESIA.UCSF.EDU UNIV OF CALIFORNIA, SAN FRANCISCO
3 PARNASSUS AVE RM S255 SAN FRANCISCO, CA 94143-0542

PERFORMING ORG.: UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISCO,
CALIFORNIA

SPONSORING ORG.: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DATES: 2005/01/00 TO 2004/30/05 FY : 2003

SUMMARY: Nosocomial pneumonia is the second most common nosocomial infection and the leading cause of death from infection acquired in the hospital. P. aeruginosa is the most frequent gram negative bacteria involved in nosocomial pneumonia, and nosocomial pneumonias associated with P.aeruginosa infections have up to a 60% mortality despite appropriate antibiotic treatment. Also patients who are chronically infected with P.aeruginosa (i.e.: cystic fibrosis, HIV patients and bronchiectasis patients) become resistant to antibiotics and may die from their infections. Thus, there is an urgent need for novel treatments of P.aeruginosa infections. The long-term objectives of this grant are to determine the cell biology of a Pseudomonas %protein%, %PcrV%. %PcrV% is part of the bacterial type III secretory system; %PcrV% is involved in the translocation of bacterial toxins by P.aeruginosa into eukaryotic cells. It is also highly homologous to LcrV, a Yersinia %protein% also involved in the translocation of that bacteria's toxins into eukaryotic cells. %Antibodies% to LcrV can protect animals from infections caused by Y. pestis and other Yersinia strains. Yet, although there are similarities between LcrV and %PcrV%, there are also important differences in the roles LcrV compared to %PcrV% in the regulation of toxin secretion in the two strains. Therefore, %PcrV% warrants independent investigation. This group has shown that %PcrV% is accessible to %antibody% neutralization, that %antibody% attachment to %PcrV% blocks the translocation of the Pseudomonas toxins into eukaryotic cells and that %antibody% to %PcrV% protects animals infected with virulent P. aeruginosa from lung injury, sepsis and death. Therefore, therapies targeting %PcrV% appears clinically useful. Finally, any virulent gram negative bacteria utilize the type III secretory system which delivers bacterial toxins into eukaryotic cells. These gram negative bacteria, including enteropathic E. coli, Yersinia, Salmonella, produce bacterial proteins and structures similar to those found in P.aeruginosa. Therefore, understanding the mechanism of %PcrV%'s role in bacterial translocation into eukaryotic cells may help in the development of other therapies targeting this widespread gram negative bacterial secretory

stem.

/3,AB/51 (Item 1 from file: 445)
ALOG(R)File 445:IMS R&D Focus
2003 IMS Health & Affiliates. All rts. reserv.

015615
ug Name: MAb, %Pseudomonas% aeruginosa, InterMune
Focus - August 27, 2001 (20010827)

MPANY INFORMATION:

Originator: InterMune; (USA); NA; NA; NA
Licensee/Licensors: %Protein% Design; (USA); NA; other; NA
Patent Assignee: %Protein% Design

UG INFORMATION:

Pharmacological Action: biotechnology; monoclonal %antibody%
Therapeutic Class Code: J7A9 (Other Unspecified Vaccines)
Clinical Indications: bacterial infection
Molecular Code: 7116950000

URRENT DEVELOPMENT STATUS:

Highest Phase: Preclinical (20)

/3,AB/52 (Item 1 from file: 19)
ALOG(R)File 19:Chem.Industry Notes
2003 Amer.Chem.Soc. All rts. reserv.

44330
Deals
urnal: BioCentury 9 (37, Pt. 2) p. B4 Date: 20010820
SN: 1097-7201 CODEN: BICEFS

InterMune Inc. (ITMN; Brisbane, CA) accepted from Protein Design Labs
c. (PDLI; Fremont, CA) a humanized version of ITMN's monoclonal antibody
against the PcrV surface protein of Pseudomonas aeruginosa under the
companies December 2000 deal.

/3,AB/53 (Item 1 from file: 42)
ALOG(R)File 42:Pharmaceuticl News Idx
2003 ProQuest Info&Learning. All rts. reserv.

704926 83507263
seudomonas% targeted by %antibody%
THOR: Anonymous
plied Genetics News, v22, n2, p10
eptember 1, 2001
DEN: AGNEEN DOCUMENT TYPE: Periodical; News JOURNAL CODE: AGN
LANGUAGE: English RECORD TYPE: Citation

5/3,AB/54 (Item 1 from file: 107)
ALOG(R)File 107:Adis R&D Insight
2003 Adis Data Information BV. All rts. reserv.

0195426 000527
RUG NAME: %Pseudomonas% vaccine
ECORD REVISION DATE: 20030410
HO ATC CODE: J07A-X - Other bacterial vaccines
PHMRA ATC CODE: J7A9 - Other specified single component
ECHANISM OF ACTION: Immunostimulants; Immunomodulators
RIGINATOR COMPANY: Russian Academy of Medical Sciences (Russia);
Nonindustrial source (Unknown); Louisiana State
University (USA)
ARENT COMPANY: Louisiana State University; Nonindustrial source;
Russian Academy of Medical Sciences

HEST PHASE: Preclinical

DEVELOPMENT STATUS: Preclinical, USA, Pseudomonal infections
No Development Reported, Russia, Pseudomonal infections

TEXT

roduction:
Pseudomonas aeruginosa is a major cause of morbidity and mortality in patients with cystic fibrosis. Organ transplant recipients are also at high risk of acquiring this infection.
The Academy of Medical Sciences in Moscow, Russia, was conducting phase I studies with a P. aeruginosa vaccine containing cell-wall protein antigens, but there have been no recent reports of ongoing development.
Researchers at the Louisiana State University, USA, are conducting preclinical studies with experimental vaccines containing P. aeruginosa outer-membrane protein F.
Researchers in the US appear to be developing a vaccine for Pseudomonas aeruginosa based on the P. aeruginosa homologue of the Yersinia V antigen.
The vaccine protected mice from subsequent challenge with P. aeruginosa in preclinical studies/1/.

COMMERCIAL SUMMARY:

Pseudomonal infections / Immunostimulant

| Company | Region | Launch Date | Peak Sales | Patent Expiry |
|---------|--------|-------------|------------|---------------|
| Shire | Wrld | 2007 | \$300m | |

Copyright (C) Lehman Brothers International. All rights reserved.

PHARMACOLOGY OVERVIEW:

Pharmacodynamics:

Protein F and synthetic peptide epitopes from protein F of Pseudomonas aeruginosa protect mice from pseudomonal pneumonia

Immunogenicity:

Induces specific antibodies in volunteers

Mechanism of action:

Immunostimulants

Immunomodulators

CLINICAL OVERVIEW:

Route(s) of Administration: Injection, Parenteral

Drug Interactions:

Unknown.

/3,AB/55 (Item 2 from file: 107)

ALOG(R) File 107:Adis R&D Insight

) 2003 Adis Data Information BV. All rts. reserv.

175254

013254

UG NAME:

Anti-PcrV antibodies - InterMune

CORD REVISION DATE: 20011120

NONYMS:

Anti-PcrV immunoglobulin G; Anti-PcrV monoclonal antibody; Anti-PcrV polyclonal antibody; Pseudomonas infections research programme - InterMune; Research programme: pseudomonal infections - InterMune

NO ATC CODE:

J01X-X - Other antibacterials

HMRA ATC CODE:

J8X - All Other Anti-Infectives

MECHANISM OF ACTION:

PcrV inhibitors; Protein inhibitors

ORIGINATOR COMPANY:

InterMune (USA); Medical College of Wisconsin (USA); University of California at San Francisco (USA)

ARENT COMPANY:

California State University; InterMune; Medical College of Wisconsin

OTHER COMPANY:

Protein Design Labs

GHEST PHASE: Preclinical

VELOPMENT STATUS: Preclinical, USA, Pseudomonal infections

TEXT

roduction:

terMune Inc. (USA) is involved in the development of anti-%PcrV% antibodies% for the potential treatment of pseudomonal infections. %PcrV% a %protein% of the type III secretory system of %Pseudomonas% aeruginosa at facilitates the virulence of these bacteria. monoclonal form of the anti-%PcrV% %antibody% has been developed by the dical College of Wisconsin, Milwaukee (Wisconsin, USA) and the University California, San Francisco (USA). In August 2001, it was announced that, per its agreement with InterMune, %Protein% Design Labs Inc. had ccessfully humanised the anti-%PcrV% monoclonal %antibody%. Under the rms of the agreement with InterMune, %Protein% Design Labs will be ttitled to annual maintenance payments and royalties on any product sales. terMune is now working towards moving the %antibody% to the clinic by the d of 2002. The %antibody% is reportedly effective in animal models of fection.

preclinical study conducted by the University of California at San ancisco and funded by InterMune have indicated that treatment with a yclonal form of anti-%PcrV% %antibody% may have potential for the rovement of lung damage and the prevention of septic shock/1/.

ARMACOLOGY OVERVIEW:

Pharmacodynamics:

Mechanism of action:

%PcrV% inhibitors

%Protein% inhibitors

INICAL OVERVIEW:

Drug Interactions:

Unknown.

/3,AB/56 (Item 1 from file: 129)

ALOG(R)File 129:PHIND(Archival)

) 2003 PJB Publications, Ltd. All rts. reserv.

722774

terMune to develop %Pseudomonas% treatment:

Scrip 2672 p15, August 24, 2001 (20010824)

STORY TYPE: B WORD COUNT: 95

/3,AB/57 (Item 2 from file: 129)

ALOG(R)File 129:PHIND(Archival)

) 2003 PJB Publications, Ltd. All rts. reserv.

690762

terMune/%Protein% Design Labs to collaborate on monoclonal %antibody%:

Scrip 2602 p10, December 20, 2000 (20001220)

STORY TYPE: B WORD COUNT: 105

/3,AB/58 (Item 1 from file: 761)

ALOG(R)File 761:Datamonitor Market Res.

) 2003 Datamonitor. All rts. reserv.

141624

WS HEADLINES HEPATITIS AND OTHER VIRAL INFECTIONS: 7.0 NEWS HEADLINES:

OTHER VIRAL INFECTIONS (CONT.)

in Title: THERAPEUTIC REVIEW VIRAL INFECTIONS

ub. Date: October 08, 2001

Source: DATAMONITOR

telephone: +44 20 7675 7000

rd Count: 991 (1 pp.)
Language: English

Country: WORLD

Industry: HEALTH CARE

Company Names (DIALOG Generated): American Medical Association ; Department of Medicine ; Disease Control ; Dynavax Technologies ; Genesto A/S ; Health Canada ; Immunology ; InterMune Inc ; Journal ; Medarex Inc ; Medical College of Wisconsin ; National Center for Infectious Diseases ; New England Journal ; New York Hospital Medical Center of Queens ; NIAID ; Oxford Health Plans ; Pittsburgh Graduate School ; Prevention ; %Protein% Design Labs Inc ; Public Health ; National Institute of Allergy and Infectious Diseases ; National Institute of Allergy and Infectious Diseases ; Therapeutic Products ; University of California San Francisco ; University of Pittsburgh Graduate School of Public Health ; University of Washington School of Medicine ; Washington School

/3,AB/59 (Item 2 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
2003 Datamonitor. All rts. reserv.

141577

CTERIAL INFECTIONS-UPDATE: 1.0 R&D UPDATE

in Title: THERAPEUTIC REVIEW
ub. Date: October 08, 2001
Source: DATAMONITOR
Telephone: +44 20 7675 7000
rd Count: 1420 (1 pp.)
Language: English

Country: WORLD

Industry: HEALTH CARE

Company Names (DIALOG Generated): Abbott Laboratories ; Antex Biologics Inc ; AntiCancer Inc ; Cystic Fibrosis Foundation Therapeutics Inc ; CDI ; Demegen Inc ; Duke University Medical Center ; Infotech Inc ; InterMune Inc ; Journal ; Medical College of Wisconsin ; Molecular Genetics ; National Academy ; New York Hospital Medical Center of Queens ; %Protein% Design Labs Inc ; State Serum Institute ; Rockefeller University ; University of California San Francisco

/3,AB/60 (Item 1 from file: 764)
DIALOG(R)File 764:BCC Market Research
2003 Business Communication Co. All rts. reserv.

182169

MMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW: %ANTIBODIES%: %ANTIBODY% DRUG
FOR %PSEUDOMONAS% INFECTION

in Title: COMMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW
ub. Date: APRIL 2002
Source: BUSINESS COMMUNICATIONS COMPANY, INCORPORATED
Telephone: (203) 853-4266
rd Count: 408 (1 pp.)
Language: English

Country: UNITED STATES

Industry: BIOTECHNOLOGY, HEALTH CARE

Company Names (DIALOG Generated): InterMune Inc ; Journal ; Medical College of Wisconsin ; %Protein% Design Labs Inc ; University of California

2003 The Gale Group. All rts. reserv.

4911 Supplier Number: 54353697
Researchers Find Way To Immunize Against Fatal Bacterium.
Tuberculosis & Airborne Disease Weekly, pNA
12, 1999
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Count: 712

,AB/18 (Item 1 from file: 20)
LOG(R)File 20:Dialog Global Reporter
2003-The Dialog Corp. All rts. reserv.

01323
Gene developed to fight deadly lung infections in critically ill
MICROBIAL BUSINESS NEWSBASE (BIOTECHNOLOGY NEWSWATCH) , p5
12, 1999
ORIGINAL CODE: FBNW LANGUAGE: English RECORD TYPE: FULLTEXT
COUNT: 101

Researchers from the Medical College of Wisconsin and the University
of California San Francisco have reported in the journal Nature Medicine
that by using an antibody against the PcrV protein, they were able to
stop the bacterium Pseudomonas aeruginosa (responsible for serious and
incurable lung infections in cystic fibrosis and critically ill patients)
from injecting its toxins.
This research was carried out on mice.

3,AB/19 (Item 1 from file: 440)
LOG(R)File 440:Current Contents Search(R)
2003 Inst for Sci Info. All rts. reserv.

242459 References: 34
TITLE: Therapeutic administration of anti-PcrV F(ab')₂ in sepsis
associated with Pseudomonas aeruginosa
AUTHOR(S): Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T;
Swanson BL; Spack EG; Wiener-Kronish JP (REPRINT)
AUTHOR(S) E-MAIL: wienerkj@anesthesia.ucsf.edu
CORPORATE SOURCE: Univ Calif San Francisco, Dept Anesthesia & Perioperative
Care, Box 0542/San Francisco/CA/94143 (REPRINT); Univ Calif San
Francisco, Dept Anesthesia & Perioperative Care, /San Francisco/CA/94143;
Univ Calif San Francisco, Dept Med, /San Francisco/CA/94143; Univ Calif
San Francisco, Cardiovasc Res Inst, /San Francisco/CA/94143; Kyoto
Prefectural Univ Med, Dept Anesthesiol & Intens Care, /Kyoto/Japan/;
InterMune Inc, /Brisbane/CA/94005
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF IMMUNOLOGY, 2001, V167, N10 (NOV 15), P5880-5886
UNIQUE ARTICLE#: 491JZ
PUBLISHER: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD
20814 USA

ISSN: 0022-1767
LANGUAGE: English DOCUMENT TYPE: ARTICLE
ABSTRACT: The effects of rabbit-derived polyclonal Ab against PcrV, a
protein involved in the translocation of type III secreted toxins of
Pseudomonas aeruginosa, was investigated in two animal models of P.
aeruginosa sepsis. In a mouse survival study, the i.v. administration of
anti-PcrV IgG after the airspace instillation of a lethal dose of A
aeruginosa resulted in the complete survival of the animals. In a rabbit
model of septic shock associated with Pseudomonas-induced lung injury,
animals treated with anti-PcrV IgG intratracheally or i.v. had significant
decreases in lung injury, bacteremia, and plasma TNF-alpha and significant
improvement in the hemodynamic parameters associated with shock compared
with animals treated in a similar manner with nonspecific control IgG. The
administration of anti-PcrV F(ab')₂ showed protective effects
comparable to those of whole anti-PcrV IgG. These results document that
the therapeutic administration of anti-PcrV IgG blocks the type III

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Delivery of Yop effector proteins by pathogenic *Yersinia* across the eukaryotic cell membrane requires LcrV, YopB and YopD. These proteins were also required for channel formation in infected erythrocytes and, using different osmolytes, the contact-dependent haemolysis assay was used to study channel size. Channels associated with LcrV were around 3 nm, whereas the homologous PcrV protein of *Pseudomonas aeruginosa* induced channels of around 2 nm in diameter. In lipid bilayer membranes, purified LcrV and PcrV induced a stepwise conductance increase of 3 nS and 1 nS, respectively, in 1 M KCl. The regions important for channel size were localized to amino acids 127-195 of LcrV and to amino acids 106-173 of PcrV. The size of the channel correlated with the ability to translocate Yop effectors into host cells. We suggest that LcrV is a size-determining structural component of the Yop translocon.

/3,AB/40 (Item 1 from file: 73)

ALOG(R) File 73:EMBASE

) 2003 Elsevier Science B.V. All rts. reserv.

390411 EMBASE No: 2001404624

Therapeutic administration of anti-PcrV F(abprime)SUB2 in sepsis associated with *Pseudomonas aeruginosa*

Shime N.; Sawa T.; Fujimoto J.; Faure K.; Allmond L.R.; Karaca T.; Anson B.L.; Spack E.G.; Wiener-Kronish J.P.

Dr. J.P. Wiener-Kronish, Box 0542, Department of Anesthesia, University of California, San Francisco, CA 94143-0542 United States

AUTHOR EMAIL: wienerkj@anesthesia.ucsf.edu

Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 2001,

167/10 (5880-5886)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 34

The effects of rabbit-derived polyclonal Ab against PcrV, a protein involved in the translocation of type III secreted toxins of *Pseudomonas aeruginosa*, was investigated in two animal models of *P. aeruginosa* sepsis. In a mouse survival study, the i.v. administration of anti-PcrV IgG after the airspace instillation of a lethal dose of *P. aeruginosa* resulted in the complete survival of the animals. In a rabbit model of septic shock associated with *Pseudomonas*-induced lung injury, animals treated with anti-PcrV IgG intratracheally or i.v. had significant decreases in lung injury, bacteremia, and plasma TNF-alpha and significant improvement in the hemodynamic parameters associated with shock compared with animals treated in a similar manner with nonspecific control IgG. The administration of anti-PcrV F(abprime)SUB2 showed protective effects comparable to those of anti-PcrV IgG. These results document that the therapeutic administration of anti-PcrV IgG blocks the type III secretion system-mediated virulence of *P. aeruginosa* and prevents septic shock and death, and that these protective effects are largely Fc independent. We conclude that Ab therapy neutralizing the type III secretion system has significant potential against lethal *P. aeruginosa* infections.

/3,AB/41 (Item 1 from file: 654)

ALOG(R) File 654:US PAT.FULL.

) FORMAT ONLY 2003 THE DIALOG CORP. All rts. reserv.

92884

Current Accession: 2000-431202

ility

Method of and compositions for immunization with the *pseudomonas* V antigen

A METHOD OF INHIBITING, MODERATING OR DIAGNOSING *PSEUDOMONAS AERUGINOSA* INFECTION IS DISCLOSED.

tracellular products which are synthesized and secreted and coordinately controlled with exoenzyme S by a type III secretory system. Our previous investigations have documented that the lung injury and dissemination of the airspace PA103 to the circulation correlated with the production of exoenzyme S by the bacteria. Two of the novel extracellular products produced and secreted with exoenzyme S are ExoU, a novel cytotoxin, and PcrV, a homolog of the Yersinia pestis V antigen, which may affect host cytokine production. Our hypothesis is that these two bacterial products are the major virulence products of P.aeruginosa and therapies directed against these products would prevent the local and systemic injury due to the dissemination seen with this infection. To prove this hypothesis, we will compare the effects of these newly discovered bacterial products to aeruginosa endotoxin in terms of their individual and combined effects on lung injury, lung inflammation and the systemic inflammatory response. We will utilize isogenic transposon PA103 strains that are selectively missing the genes for ExoU, for PcrV or both of these genes. These 2 recombinant proteins are also available for experiments and we have obtained specific endotoxin antagonists and genetically deficient mice for lipopolysaccharide binding protein to determine the effects of these products in animals resistant to the effects of endotoxin. We will determine whether these two bacterial products are responsible for IL-10 production in vivo and if blockade of the IL-10 improves local host defense.

1/3,AB/44 (Item 2 from file: 156)

ALOG(R)File 156:ToxFile

format only 2003 The Dialog Corporation. All rts. reserv.

900390 NLM Doc No: CRISP/2000/AI44101-01A2 Sec. Source ID:

CRISP/2000/AI44101-01A2

BIOLOGY OF PcrV

WIENER-KRONISH JP

UNIV OF CALIFORNIA, SAN FRAN, 374 PARNASSUS AVE, SAN FRANCISCO, CA

94143-0648

Source: Crisp Data Base National Institutes of Health

City or State: CALIFORNIA Zip Code: 94143-0648

Pub. Year: 2000

Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH

SERVICE; NATIONAL INSTITUTES OF HEALTH, NATIONAL INSTITUTE OF ALLERGY AND

INFECTIOUS DISEASES

Award Type: Grant

Document type: Research

Languages: ENGLISH

Record type: Completed

Nosocomial pneumonia is the second most common nosocomial infection and the leading cause of death from infection acquired in the hospital. P.aeruginosa is the most frequent gram negative bacteria involved in nosocomial pneumonia, and nosocomial pneumonias associated with P.aeruginosa infections have up to a 60% mortality despite appropriate antibiotic treatment. Also patients who are chronically infected with P.aeruginosa (i.e.: cystic fibrosis, HIV patients and bronchiectasis patients) become resistant to antibiotics and may die from their infections. Thus, there is an urgent need for novel treatments of P.aeruginosa infections. The long-term objectives of this grant are to determine the cell biology of a Pseudomonas protein, PcrV. PcrV is part of the bacterial type III secretory system; PcrV is involved in the translocation of bacterial toxins by P.aeruginosa into eukaryotic cells. It is also highly homologous to LcrV, a Yersinia protein also involved in the translocation of that bacteria's toxins into eukaryotic cells. Antibodies to LcrV can protect animals from infections caused by Y. pestis and other Yersinia strains. Yet, although there are similarities between LcrV and PcrV, there are also important differences in the roles LcrV compared to PcrV in the regulation of toxin secretion in the two strains. Therefore, PcrV warrants independent investigation. This group has shown that PcrV is accessible to antibody neutralization, that antibody attachment to PcrV blocks the translocation of the Pseudomonas toxins into eukaryotic cells and that antibody to PcrV protects animals infected with virulent P. aeruginosa from lung injury, sepsis and death. Therefore, therapies targeting PcrV appears clinically useful. Finally,

ny virulent gram negative bacteria utilize the type III secretory system
ich delivers bacterial toxins into eukaryotic cells. These gram negative
acteria, including enteropathic E. coli, Yersinia, Salmonella, produce
acterial proteins and structures similar to those found in P.aeruginosa.
erefore, understanding the mechanism of %PcrV% 's role in bacterial
anslocation into eukaryotic cells may help in the development of other
erapies targeting this widespread gram negative bacterial secretory
stem.

/3,AB/45 (Item 1 from file: 135)
ALOG(R)File 135:NewsRx Weekly Reports
) 2003 NewsRx. All rts. reserv.

00052436 (USE FORMAT 7 OR 9 FOR FULLTEXT)
noclonal %Antibody% Developed For Treatment/Prevention Of Infection
otech Week, September 19-26, 2001, p.19

CUMENT TYPE: Expanded Reporting LANGUAGE: English
CORD TYPE: FULLTEXT
RD COUNT: 418

/3,AB/46 (Item 2 from file: 135)
ALOG(R)File 135:NewsRx Weekly Reports
) 2003 NewsRx. All rts. reserv.

00040190 (USE FORMAT 7 OR 9 FOR FULLTEXT)
ntibody% Humanization Agreement Announced
otech Week, December 20, 2000, p.22

CUMENT TYPE: Research News LANGUAGE: English
CORD TYPE: FULLTEXT
RD COUNT: 189

/3,AB/47 (Item 1 from file: 9)
ALOG(R)File 9:Business & Industry(R)
) 2003 Resp. DB Svcs. All rts. reserv.

57021 Supplier Number: 02457021
terMune Pharmaceutical, Inc. Researchers Find Way To Immunize Against
Fatal Bacterium
nterMune Pharmaceutical signs licensing agreement with university
researchers to develop an %antibody% therapy and vaccine against the
%Pseudomonas% aeruginosa bacterium)
niel J. DeNoon's Insider Newsfile, p N/A
ril 12, 1999
CUMENT TYPE: Newsletter (United States)
NGUAGE: English RECORD TYPE: Fulltext
RD COUNT: 713

STRACT:
terMune Pharmaceutical Inc has signed a licensing agreement with
searchers from the University of California (San Francisco) and the
dical College of Wisconsin to develop an %antibody% therapy and vaccine
ainst the %Pseudomonas% aeruginosa bacterium, which is responsible for
st hospital-acquired pneumonia deaths. This virulent class of microbes
s become very resistant to antibiotics. However, the research group
eveloped an alternative to antibiotics to fight the microbes. Over \$2
l/yr are spent to fight hospital pneumonia in the US. The researchers
ve developed an %antibody% against one of the proteins that delivers
tal toxins to host cells. The %antibody% has been shown to block
seudomonas% from delivering toxins into lung cells and has also shown its
ility to offer immunity against the %Pseudomonas% bacterium. The article
rther discusses the research collaboration.

/3,AB/48 (Item 1 from file: 266)

344625

IDENTIFYING NO.: 1R41HL67600-01A1 AGENCY CODE: CRISP

Animal Testing of a Blocking %Antibody% of %PcrV%

PRINCIPAL INVESTIGATOR: SAWA, TEIJI

ADDRESS: SAWAT@ANAESTHESIA.UCSF.EDU UNIVERSITY OF CALIFORNIA, SAN FR 513
RNASSUS AVE, RM S255 SAN FRANCISCO, CA 94143-0542

PERFORMING ORG.: INTERMUNE PHARMACEUTICALS, INC., BURLINGAME, CALIFORNIA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

DATES: 2001/01/02 TO 2006/30/03 FY : 2002

SUMMARY: DESCRIPTION (provided by applicant): This grant will determine the efficacy of a humanized monoclonal %antibody% in treating a lethal pseudomonas% -induced lung injury. We have shown that the airspace instillation of a strain of %Pseudomonas% aeruginosa that contains the type III secretion system predictably causes lung necrosis, sepsis and death (J Clin Invest 1999). We have also shown that the systemic administration of polyclonal %antibody% raised against recombinant %PcrV%, a type III bacterial protein% involved in translocating the bacterial toxins into eukaryotic cells, prevented lung injury and death in mice pretreated with the %antibody% (Nature Med 1999). More recently, we have identified a mouse monoclonal %antibody% that when administered prior to the bacterial instillation, prevented mortality in mice airspace-infected with the virulent %Pseudomonas%. The proposed experiments will determine whether the systemic or lung administration of a humanized monoclonal %antibody% after the airspace instillation of the virulent %Pseudomonas% improves lung mechanics, gas exchange and/or improves the septicemia in airspace-infected, anesthetized rabbits. These results will be critical for deciding how to plan a clinical trial; the results will determine whether the %antibody% should be utilized as a therapy or as a prophylactic treatment. PROPOSED COMMERCIAL APPLICATIONS: %Pseudomonas% aeruginosa is a major cause of hospital infection, accounting for 20% of nosocomial pneumonias, 10-15% of nosocomial urinary tract infections, and 10% of sepsis. In addition, P. aeruginosa infection is the major cause of mortality in cystic fibrosis. Current treatment is associated with a high rate of antibiotic resistance and a 25-50% failure rate. The proposed treatment provides a novel approach to the prevention of P. aeruginosa infection in patients at high risk for this infection, including patients on ventilators, burn patients, patients with in-dwelling catheters, immunotopenic patients, and patients with cystic fibrosis.

3,AB/49 (Item 2 from file: 266)

42184

IDENTIFYING NO.: 5R01HL59239-04 AGENCY CODE: CRISP

HOST RESPONSE TO CYTOTOXIC PROTEINS

PRINCIPAL INVESTIGATOR: WIENER-KRONISH, JEANINE P

ADDRESS: JWK@JEMO.UCSF.EDU UNIV. OF CALIFORNIA, SAN FRANCIS UNIVERSITY OF
CALIFORNIA SAN FRANCISCO, CALIFORNIA 94143

PERFORMING ORG.: UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISCO,
CALIFORNIA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

DATES: 2007/06/98 TO 2006/30/03 FY : 2001

SUMMARY: High mortality rates are associated with nosocomial lung infections due to P.aeruginosa. As current antibiotic therapies are associated with a 50-80 percent mortality in this infection, improved methods for prevention and therapy clearly are needed. The airspace instillation of PA103, a cytotoxic strain of P.aeruginosa, recreates the lung injury and sepsis seen in many of the patients with nosocomial pneumonia; the instillation of the bacteria causes lung epithelial injury, bacteremia, organ failure and death of experimental animals. Over the last years, our two laboratories have collaborated on bacterial genetic experiments and animal physiology experiments that have led to the discovery of novel P.aeruginosa extracellular products which are synthesized and secreted and coordinately controlled with exoenzyme S by a

cretion system-mediated virulence of *P. aeruginosa* and prevents septic shock and death, and that these protective effects are largely Fc dependent. We conclude that Ab therapy neutralizing the type III secretion system has significant potential against lethal *P. aeruginosa* infections.

/3,AB/20 (Item 2 from file: 440)
ALOG(R)File 440:Current Contents Search(R)
2003 Inst for Sci Info. All rts. reserv.

359287 References: 29

TITLE: Sera from adult patients with cystic fibrosis contain antibodies to *Pseudomonas aeruginosa* type III apparatus

THOR(S): Moss J; Ehrmantraut ME; Banwart BD; Frank DW; Barbieri

JT (REPRINT)

THOR(S) E-MAIL: toxin@mcw.edu

CORPORATE SOURCE: Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701

Watertown Plank Rd/Milwaukee//WI/53226 (REPRINT); Med Coll Wisconsin,

Dept Microbiol & Mol Genet, /Milwaukee//WI/53226; NHLBI, NIH,

/Bethesda//MD/20892; Med Coll Wisconsin, Dept Pediat,

/Milwaukee//WI/53226

PUBLICATION TYPE: JOURNAL

PUBLICATION: INFECTION AND IMMUNITY, 2001, V69, N2 (FEB), P1185-1188

ORIGINAL ARTICLE#: 394MW

PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904

USA

ISSN: 0019-9567

LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: Expression of type III proteins of *Pseudomonas aeruginosa* in patients with cystic fibrosis (CF) was investigated by measuring the immune response against components of the type III pathway. Twenty-three of the 33 sera contained antibodies against PcrV, a protein involved in translocation of type III cytotoxins into eukaryotic cells, and 11 of 33 had antibodies against ExoS, while most CF sera contained antibodies against PopB and PopD, components of the type III apparatus. These data indicate that *P. aeruginosa* commonly expresses components of the type III translocation apparatus in adult CF patients.

/3,AB/21 (Item 1 from file: 349)
ALOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

0930432

METHOD AND COMPOSITIONS FOR IMMUNIZATION WITH THE *PSEUDOMONAS* V ANTIGEN
PROCEDURE ET COMPOSITIONS D'IMMUNISATION AVEC L'ANTIGENE V DE *PSEUDOMONAS*

Patent Applicant/Assignee:

MCW RESEARCH FOUNDATION INC, 8701 Watertown Plank Road, Milwaukee, WI 53226, US, US (Residence), US (Nationality), (For all designated states except: US)

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 1111 Franklin Street, 12th floor, Oakland, CA 94607, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

FRANK Dara W, 5425 West Hayes Avenue, West Allis, WI 53219, US, US (Residence), US (Nationality), (Designated only for: US)

WIENER-KRONISH Jeannine, 1908 16th Avenue, San Francisco, CA 94116, US, US (Residence), US (Nationality), (Designated only for: US)

YAHN Timothy L, 302 Olde Hickory Ridge, Coralville, IA 52241, US, US (Residence), US (Nationality), (Designated only for: US)

SAWA Teiji, 1251 17th Avenue #6, San Francisco, CA 94122, US, US (Residence), US (Nationality), (Designated only for: US)

FRITZ Robert B, 3205 South Vermont Avenue, Milwaukee, WI 53207, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

BAKER Jean C (agent), Quarles & Brady LLP, 411 East Wisconsin Avenue,

diagnostic et de therapeutique, parmi lesquelles l'immunisation passive et active, ainsi que des methodes de prevention de la colonisation par Borrelia chez l'animal. Il est propose d'utiliser ces segments d'ADN et les peptides qui en sont derives pour la preparation de vaccins et comme proteines porteuses dans des formulations de vaccins, ainsi que dans la formulation de compositions destinees a la prevention de la maladie de Lyme.

/3,AB/32 (Item 1 from file: 399)

ALOG(R)File 399:CA SEARCH(R)

) 2003 American Chemical Society. All rts. reserv.

137323925 CA: 137(22)323925x JOURNAL

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV

AUTHOR(S): Frank, Dara W.; Vallis, Amy; Wiener-Kronish, Jeanine P.; Y-Burman, Arup; Spack, Edward G.; Mullaney, Brian P.; Megdoud, Mehdi; Marks, James D.; Fritz, Robert; Sawa, Teiji

LOCATION: Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI, USA

JOURNAL: J. Infect. Dis. (Journal of Infectious Diseases) DATE: 2002

VOLUME: 186 NUMBER: 1 PAGES: 64-73 CODEN: JIDIAQ ISSN: 0022-1899

LANGUAGE: English PUBLISHER: University of Chicago Press

/3,AB/33 (Item 2 from file: 399)

ALOG(R)File 399:CA SEARCH(R)

) 2003 American Chemical Society. All rts. reserv.

137184454 CA: 137(13)184454c PATENT

Pseudomonas aeruginosa V antigen and antibodies for diagnosis, prognosis and treatment of infection by Pseudomonas aeruginosa

INVENTOR(AUTHOR): Frank, Dara W.; Wiener-Kronish, Jeannine; Yahr, Timothy; Sawa, Teiji; Fritz, Robert B.

LOCATION: USA

ASSIGNEE: Mcw Research Foundation, Inc.; The Regents of the University of California

PATENT: PCT International ; WO 200264161 A2 DATE: 20020822

APPLICATION: WO 2002US2382 (20020125) *US 770916 (20010126) *US PV264795 0010129)

PAGES: 63 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/104A;

A61K-048/00B; G01N-033/569B; C07K-016/12B; A61K-039/40B; A61P-031/04B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; MR; NE; SN; TD; TG

/3,AB/34 (Item 3 from file: 399)

ALOG(R)File 399:CA SEARCH(R)

) 2003 American Chemical Society. All rts. reserv.

131057511 CA: 131(5)57511v JOURNAL

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury

AUTHOR(S): Sawa, Teiji; Yahrs, Timothy L.; Ohara, Maria; Kurahashi, Miyoyasu; Gropper, Michael A.; Wiener-Kronish, Jeanine P.; Frank, Dara W.

LOCATION: Cardiovascular Research Institute, University of California, San Francisco, CA, 94143-0542, USA

JOURNAL: Nat. Med. (N. Y.) DATE: 1999 VOLUME: 5 NUMBER: 4 PAGES:

2-398 CODEN: NAMEFI ISSN: 1078-8956 LANGUAGE: English PUBLISHER:

Future America

/3,AB/35 (Item 1 from file: 5)
ALOG(R) File 5: Biosis Previews(R)
) 2003 BIOSIS. All rts. reserv.

870701 BIOSIS NO.: 200200499522

velopment and characterization of monoclonal %antibody% to %Pseudomonas%
aeruginosa type III secreted %protein% %PcrV%.

THOR: Sawa T(a); Vallis A; Spack E G; Frank D W; Wiener-kronish J P(a)

THOR ADDRESS: (a)Univ. of CA, San Francisco, San Francisco, CA**USA

JOURNAL: Abstracts of the Interscience Conference on Antimicrobial Agents
and Chemotherapy 41p56 2001

DIUM: print

CONFERENCE/MEETING: 41st Annual Meeting of the Interscience Conference on
Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA September
-25, 2001

CORD TYPE: Abstract

LANGUAGE: English

STRACT: Background: We reported that P. aeruginosa V-antigen (%PcrV%) is
a protective antigen against P. aeruginosa infection and rabbit
polyclonal %antibody% to %PcrV% can neutralize the virulence associated
with the type III secretion system (Nature Medicine, 5:392, 1999). We
developed a murine monoclonal %antibody% against %PcrV%. We examined the
effects of this %antibody% on lethal P. aeruginosa pneumonia in our mouse
model and compared it to rabbit anti-%PcrV% IgG. Method: Murine
monoclonal %antibodies% against %PcrV% were produced by hybridoma cells;
%antibody% blocking functions against type III secretion system were
tested in our mouse model of P. aeruginosa pneumonia. Purified monoclonal
%antibody% was mixed with a lethal dose (5X10⁵ CFU/mouse) of cytotoxic P.
aeruginosa (PA103) and directly instilled into the lungs of mice.
Survival of mice was monitored for a week. The %antibody% was also tested
for its effects in passive immunization in infected mice. Results: The
clone m166 which showed higher affinity in preliminary screening and also
demonstrated potent protective effects on the survival of mice infected
with PA103. Eighty percent of mice survived after the instillation of a
lethal dose of PA103 with 10 micrograms of m166, while no mice survived
without receiving IgG. Passive immunization, 100 micrograms of m166
injected intraperitoneally 1 hour before the instillation of a lethal
dose of PA103 saved 90% of mice infected with PA103 while control mice
receiving saline instead of IgG all died in two days. Conclusion:
Specific murine monoclonal %antibody% against %PcrV% showed comparable
potency to a rabbit polyclonal anti-%PcrV% IgG in an animal model of P.
aeruginosa infection. The monoclonal %antibody% against %PcrV% has the
potential to be a therapeutic agent in P. aeruginosa infection.

1

3,AB/36 (Item 1 from file: 636)
ALOG(R) File 636: Gale Group Newsletter DB(TM)
2003 The Gale Group. All rts. reserv.

57589 Supplier Number: 77275772

er News To Note. (Brief Article)

WORLD Today, v12, n160, pNA

ust 17, 2001

guage: English Record Type: Fulltext

icle Type: Brief Article

ument Type: Magazine/Journal; Trade

d Count: 1121

3,AB/37 (Item 1 from file: 155)

LOG(R) File 155: MEDLINE(R)

format only 2003 The Dialog Corp. All rts. reserv.

48119 21659906 PMID: 11801671

ersinia enterocolitica evasion of the host innate immune response by V

antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice.

Sing Andreas; Roggenkamp Andreas; Geiger Anna M; Heesemann Jurgen
Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie,
Pettenkoferstrasse 9a, 80336 Munich, Germany.

Journal of immunology (Baltimore, Md. - 1950) (United States) Feb 1
2002, 168 (3) p1315-21, ISSN 0022-1767 Journal Code: 2985117R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The virulence-associated V Ag (LcrV) of pathogenic Yersinia species is part of the translocation apparatus, required to deliver antihost effector proteins (Yersinia outer proteins) into host cells. An orthologous protein (denoted as PcrV) has also been identified in the ExoS regulon of Pseudomonas aeruginosa. Additionally, it is known that LcrV is released by yersiniae into the environment and that LcrV causes an immunosuppressive effect when injected into mice. In this study, we demonstrate for the first time that rLcrV, but not PcrV, is capable of suppressing TNF-alpha production in zymosan A-stimulated mouse macrophages and the human monocytic Mono-Mac-6 cell line. The underlying mechanism of TNF-alpha suppression could be assigned to LcrV-mediated IL (IL)-10 production, because 1) LcrV induces IL-10 release in macrophages, 2) anti-IL-10 Ab treatment completely abrogated TNF-alpha suppression, and 3) TNF-alpha suppression was absent in LcrV-treated macrophages of IL-10-deficient (IL-10-/-) mice. The relevance of LcrV-mediated immunosuppression for the pathogenicity of yersiniae became evident by experimental infection of mice; in contrast to wild-type mice, IL-10-/- mice were highly resistant against Yersinia infection, as shown by lower bacterial load in spleen and liver, absent abscess formation in these organs, and survival.

3,AB/38 (Item 2 from file: 155)

LOG(R)File 155:MEDLINE(R)

format only 2003 The Dialog Corp. All rts. reserv.

506986 21391858 PMID: 11500471

PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.

Holder I A; Neely A N; Frank D W

Department of Microbiology, Shriners Hospital for Children, Cincinnati,
Ohio 45229, USA. iaholder@juno.com

Infection and immunity (United States) Sep 2001, 69 (9) p5908-10,

ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls. Survival was non-O serotype specific and correlated with a reduced systemic microbial load. Infection with a high-level toxin A-producing strain required supplemental antitoxin treatment to enhance survival.

3,AB/39 (Item 3 from file: 155)

LOG(R)File 155:MEDLINE(R)

format only 2003 The Dialog Corp. All rts. reserv.

46146 21105993 PMID: 11169103

LcrV is a channel size-determining component of the Yop effector translocator of Yersinia.

Olmstrom A; Olsson J; Cherepanov P; Maier E; Nordfelth R; Pettersson J; Z R; Wolf-Watz H; Forsberg A

Department of Microbiology, FOA NBC-Defence, S-901 82 Umea, Sweden.

Molecular microbiology (England) Feb 2001, 39 (3) p620-32, ISSN

0950-382X Journal Code: 8712028